- Home
- WWW vs XOMAP Comparison
WWW vs XOMAP Comparison
Compare WWW & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWW
- XOMAP
- Stock Information
- Founded
- WWW 1883
- XOMAP N/A
- Country
- WWW United States
- XOMAP United States
- Employees
- WWW N/A
- XOMAP 13
- Industry
- WWW Shoe Manufacturing
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- WWW Consumer Discretionary
- XOMAP Health Care
- Exchange
- WWW Nasdaq
- XOMAP Nasdaq
- Market Cap
- WWW N/A
- XOMAP N/A
- IPO Year
- WWW N/A
- XOMAP N/A
- Fundamental
- Price
- WWW $10.79
- XOMAP $25.95
- Analyst Decision
- WWW Strong Buy
- XOMAP
- Analyst Count
- WWW 8
- XOMAP 0
- Target Price
- WWW $18.75
- XOMAP N/A
- AVG Volume (30 Days)
- WWW 1.7M
- XOMAP N/A
- Earning Date
- WWW 05-07-2025
- XOMAP N/A
- Dividend Yield
- WWW 3.70%
- XOMAP N/A
- EPS Growth
- WWW N/A
- XOMAP N/A
- EPS
- WWW 0.58
- XOMAP N/A
- Revenue
- WWW $1,755,000,000.00
- XOMAP N/A
- Revenue This Year
- WWW $4.50
- XOMAP N/A
- Revenue Next Year
- WWW $5.34
- XOMAP N/A
- P/E Ratio
- WWW $18.64
- XOMAP N/A
- Revenue Growth
- WWW N/A
- XOMAP N/A
- 52 Week Low
- WWW $9.36
- XOMAP N/A
- 52 Week High
- WWW $24.64
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- WWW 37.04
- XOMAP 52.85
- Support Level
- WWW $10.46
- XOMAP $24.96
- Resistance Level
- WWW $11.56
- XOMAP $26.10
- Average True Range (ATR)
- WWW 1.15
- XOMAP 0.38
- MACD
- WWW -0.04
- XOMAP 0.03
- Stochastic Oscillator
- WWW 22.96
- XOMAP 76.74
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.